CClinicalTrials.gg
CompletedNCT06126250Updated Nov 13, 2023

Safety and Efficacy of U-Shaped Sonic Toothbrush on Plaque and Gingivitis

An interventional study of Power sonic toothbrush and Manual toothbrush in Plaque Induced Gingivitis, sponsored by Lander Enterprises, LLC. Completed at 1 site in United States. Open to participants aged 5 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-13.

Sponsored by Lander Enterprises, LLC · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
5 Years to 65 Years
Sex
All
01

Study summary

The goal of this 30 day, randomized, two group, parallel, examiner-blind clinical study is to evaluate the safety and efficacy of AutoBrush® 360° U-shaped Sonic Toothbrush on supragingival dental plaque and gingivitis, compared to an American Dental Association (ADA) reference manual soft toothbrush. The extent of gingival abrasion and recession and oral safety will be evaluated.

Read the detailed description

This single-center, randomized, controlled, examiner-blind, 30-day parallel designs study will consist of Screening and Baseline visits with approximately 80 subjects (age 5-65 years) who will read and sign an informed consent form and assent form, be assessed for evidence of gingivitis and plaque according to the Modified Gingival Index (MGI) and the Lobene-Soparkar Modification of Turesky Modified Quigley-Hein Plaque Index (LSPI) at Baseline, and days 15 and 30 post-baseline. Oral safety, gingival recession and gingival abrasion will be measured at all visits. Subjects will be randomly assigned to one of two groups: twice daily brushing with a fluoride toothpaste and 1) two-minute brushing with ADA reference standard manual toothbrush, or 2) 30-second brushing with AutoBrush® 360° U-shaped Sonic Toothbrush.

02

Conditions studied

  • Plaque Induced Gingivitis

Browse trials for

03

In context

Gingivitis

590 studies on the registry are indexed under Gingivitis; 104 are open to participants now.

This study's enrollment of 76 is above the median of 64 across 478 interventional studies indexed under Gingivitis.

Browse Gingivitis studies →

Lead sponsor

Lander Enterprises, LLC is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • generally healthy males and females at least 5 to 65 years of age.
  • If under age 18, willing to provide assent to participate and consent from a parent or legal guardian prior to being entered into the study; If 18 years of age or older, is able to read, sign and receive a copy of the signed informed consent form.
  • regular manual toothbrush users and able to brush their own teeth on a daily basis.
  • In good health based on medical history review by the investigator.
  • willing to refrain from all oral hygiene for approximately 12-16 hours prior to each study visit and discontinue eating and drinking for approximately 30 minutes prior to each study visit, with the exception of sips of water.
  • Have a minimum of 18 natural teeth, in the adult dentition, with scorable facial and lingual surfaces. If under the age of 12, must have at least 12 fully erupted teeth, primary or permanent teeth. Partially erupted permanent teeth and primary teeth that are loose or in process of exfoliation will not be included in the tooth count. Teeth that are grossly carious, orthodontically banded, exhibiting general cervical abrasion and/or enamel abrasion, > 2 mm gingival recession will not be included in the tooth count.
  • Present with a gingival index score ≥ 1.75 according to the Modified Gingival Index at Baseline, a plaque index score > 1.80 according to the Lobene-Soparkar Modification of the Turesky Modification of the Quigley-Hein Plaque Index, following a 12 to 16-hour plaque accumulation period at Baseline.
  • willing and able to refrain from dental treatment during the course of the study, except on an emergency basis.

Exclusion criteria

Exclusion Criteria:

  • history of adverse effects, oral soft or hard tissue sensitivity, to any ingredient in the test materials.
  • Self-reported serious medical conditions.
  • Self-reported as pregnant or nursing.
  • Under treatment for a heart condition requiring use of pacemaker.
  • Have any condition, in the opinion of the investigator, that would place the subject at increased risk or preclude the subject's full compliance with or completion of the study?
  • Require antibiotic premedication prior to dental procedures.
  • Have had antibiotic, anti-inflammatory, anti-coagulant medication or chemotherapeutic antiplaque/antigingivitis therapy within 30 days of screening exams.
  • participated in any study involving oral care products, concurrently or within the 30 days of screening exams.
  • Unwilling to discontinue use of other oral hygiene products for the duration of the study.
  • Present use of any tobacco products.
  • Presence of severe periodontal disease or being actively treated for periodontal disease.
  • Have grossly carious, fully crowned, or extensively restored teeth.
  • Have orthodontic appliances, peri/oral piercings, or removable partial dentures.
  • Have significant oral soft tissue pathology based on a visual examination.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    U-shaped power toothbrush

    Device: U-shaped Power Toothbrush with fluoride toothpaste

    Device: Power sonic toothbrush

  • Placebo comparator
    Manual Toothbrush

    Device: Soft Manual Toothbrush with fluoride toothpaste

    Device: Manual toothbrush

Interventions

  • DevicePower sonic toothbrush

    Subjects will brush twice daily for 30 seconds using a fluoride toothpaste.

    Also known as: AutoBrush 360 U-Shaped power toothbrush

  • DeviceManual toothbrush

    Subjects will brush twice daily for 2 minutes using a fluoride toothpaste.

    Also known as: ADA Reference standard soft manual toothbrush

06

What researchers measure

Primary outcomes

  1. Gingivitis: Modified Gingival Index (MGI)

    Gingival Inflammation, assessed on a 5-point scale (0 to 4), will be scored in six areas (disto-buccal, mid-buccal and mesio-buccal, disto-lingual, mid-lingual and mesio-lingual) of all scorable teeth using criteria: 0 = Normal (absence of inflammation), 1 = Mild inflammation (slight change in color, little change in texture) of any portion of the entire gingival unit; 2 = Mild inflammation of the entire gingival unit; 3 = Moderate inflammation (moderate glazing, redness, edema, and/or hypertrophy) of the gingival unit; 4 = Severe inflammation (marked redness and edema/hypertrophy, spontaneous bleeding, or ulceration) of the gingival unit.

    Time frame: Whole mouth mean change in MGI scores at Day 30.

  2. Plaque: Lobene-Soparkar Modification of Turesky Modification of Quigley-Hein Plaque Index (LSPI)

    Plaque will be disclosed using a red disclosing solution and each tooth will be scored in six areas (disto-buccal, mid-buccal and mesio-buccal, disto-lingual, mid-lingual and mesio-lingual), according to the criteria noted below: 0 = No plaque; 1 = Separate flecks or discontinuous band of plaque at the gingival (cervical) margin; 2 = Thin (up to 1 mm), continuous band of plaque at the gingival margin; 3 = Band of plaque wider than 1 mm but less than 1/3 of tooth surface area; 4 = Plaque covering 1/3 or more, but less than 2/3 of tooth surface area; 5 = Plaque covering 2/3 or more of tooth surface area.

    Time frame: Whole mouth mean change in LSPI scores at Day 30, immediate post-brushing (Pre- to Post-Brushing scores)

Secondary outcomes

  1. Gingivitis

    Whole mouth MGI, Gumline MGI, Proximal, Mean distal score of the last posterior tooth in each quadrant.

    Time frame: Change from Baseline at Day 15 and Day 30]

  2. Plaque

    LSPI: Whole mouth, Gumline, Proximal, distal score of the last posterior tooth in each quadrant.

    Time frame: Change from Baseline at Day 15 and Day 30

  3. Safety: gingival recession

    Gingival recession measurements (mm) will be carried out at six sites per tooth (mesio-buccal, mid-buccal, distobuccal, mesio-lingual, mid-lingual, and disto-lingual). Recession will be measured as the visible distance from the cemento-enamel junction (CEJ) to the gingival margin.

    Time frame: Changes from Baseline at Day 15 and Day 30

  4. Safety: gingival abrasion

    Gingival Abrasion will be assessed with a 2-tone disclosing solution to help visualize abraded areas of the oral epithelium. Gingival tissues of each tooth will be divided into 3 areas on both the facial and lingual surfaces, as illustrated in Fig. 1: marginal (cervical free gingiva), interdental (papillary free gingiva) and mid-gingival (attached gingiva). If abrasion is present, the site will be recorded as small (≤2 mm), medium (3-5 mm) and large (\>5 mm). If no abrasion is present, the site will be recorded as "0".

    Time frame: Changes from Baseline at Day 15 and Day 30

07

Study locations

1 site
  • Timber Falls Dental Research
    Fort Wayne, Indiana 46825, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06126250
Lead sponsor
Lander Enterprises, LLC
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Sep 11, 2023
Primary completion
Oct 27, 2023
Completion
Oct 27, 2023
Last update
Nov 13, 2023

Study contacts

Robert T. Nierman, DMD, MS
principal investigator · Timber Falls Dental Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion